Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
2021 · Nature Medicine · 400 citations
https://doi.org/10.1038/s41591-021-01462-y
A
Amod A. Sarnaik
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
314
Papers
7.3K
Citations
45
h-index
97
i10-index
Amod A. Sarnaik is an academic researcher from Lunenfeld-Tanenbaum Research Institute. The author has contributed to research in topics: CAR-T cell therapy research & Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers. The author has an h-index of 45, co-authored 267 publications.
ORCID: 0000-0002-2337-5898Papers by this author
worksLifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
2021 · Journal of Clinical Oncology · 382 citations
https://doi.org/10.1200/jco.21.00612
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
2022 · Journal for ImmunoTherapy of Cancer · 285 citations
https://doi.org/10.1136/jitc-2022-005755
Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics
2014 · Molecular & Cellular Proteomics · 57 citations
https://doi.org/10.1074/mcp.m113.037424
Expression of MXI1, a Myc Antagonist, Is Regulated by Sp1 and AP2
1999 · Journal of Biological Chemistry · 37 citations
https://doi.org/10.1074/jbc.274.40.28794
Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma
2017 · Journal of the National Comprehensive Cancer Network · 36 citations
https://doi.org/10.6004/jnccn.2017.0047
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat